GILD and Germany-based Tubulis collaborate to discover and develop an antibody-drug conjugate against a solid tumor target.

Gilead Sciences, Inc. (Nasdaq: GILD) and Tubulis today announced that they have entered into an exclusive option and license ...

Gilead isn’t the only Big Pharma to take an interest in Tubulis’ ADC tech. BMS paid the company $23 million upfront in April ...

The deal with Tubulis gives Gilead access to the German biotech's ADC technology platform, designed to make ADCs more stable, ...

Gilead Sciences, Inc. (Nasdaq: GILD) and Tubulis Tuesday said they have entered into an option and license agreement to discover and ...

The deal with Tubulis will help Gilead regain its footing in the ADC space following the withdrawal of Trodelvy in bladder ...

Gilead (GILD) and Tubulis announced that they have entered into an exclusive option and license agreement to discover and develop an ...

US antiviral giant Gilead Sciences has entered into an exclusive option and license agreement with Germany’s Tubulis to discover and develop an antibody-drug conjugate (ADC) against a solid tumor ...

Sanofi just made its largest investment thus far in China. The company has committed just over $1 billion to build a new ...

Genetic Immunity, a leader in plasmid DNA-based immunotherapies, and VectorBuilder, a global specialist in gene delivery solutions, announced a strategic partnership to advance Genetic Immunity's ...

Lexie Hearing has been named to Inc.'s 2024 Best in Business list in the Health Products category. Inc.'s annual Best in Business Awards celebrate the exceptional achievements and contributions of ...

Since the start of the year, Ipsen has bolstered its oncology pipeline with two ADC alliances – with Foreseen Bio and Sutro ...